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Table 3 EfIect of DIDS and chloride absence on acid-loading rate 
(Jload) following a 10% CO2 prepulse 
D IDS-sensitive 
(HCO;;-
Control DIDS No chloride transport) 
-AVP 630±22 62±3 51 ±5 568 
+AVP 1,504±76 119±9 80±3 1,385 
AVP dep. 874±35 57±8 31±7 717 
% Stimulation 140± 11 143 
Fluxes calculated as in Table 1, but at pH 7.7. ßHCO:; was 114.9 mM 
per pH unit at pHi 7.7. 
crucial mitogenic signal. It could be advantageous for an acti-
vated cell to maintain a steady-state pHi dose to the unactivated 
level given the sensitivity to pH of nearly all cellular processes. 
Such a steady-state pHi is achieved when processes that acid-
load the cell (for example Na+-independent CI-/HCO:J 
exchange) balance those that alkali-load it (for example, 
Na+/H+) and Na+-dependent Cl-/HC0:J exchange). It would 
also be advantageous however, for the activated cell to be able 
to recover more rapidly from acid and alkali loads. The require-
ments for both a near-normal steady-state pHi and enhanced 
pHi regulation can only be met if increases in acid loading and 
acid extrusion by the growth factor are comparable. This is 
precisely the response of the mesangial cell to A VP: application 
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Peptides that are antigenic for T lymphocytes are ligands for two 
receptors, the class I or 11 glycoproteins that are encoded by genes 
in the major histocompatibility complex, and the idiotypic Q' / ß 
chain T-cell antigen receptorl - 9 • That a peptide must bind to an 
MHC molecule to interact with a T-cell antigen receptor is the 
molecular basis of the MHC restriction of antigen-recognition by 
T lymphocytesIO,lI. In such a trimolecular interaction the amino-
acid sequence of the peptide must specify the contact with both 
receptors: agretope residues bind to the MHC receptor and epitope 
residues bind to the T -cell antigen receptor12,13. From a compilation 
of known antigenic peptides, two algorithms have been proposed 
to predict antigenic sites in proteins. One algorithm uses linear 
motifs in the sequencel4, whereas the other considers peptide 
conformation and predicts antigenicity for amphipathic Q'-
helices15,16. We report here that a systematic delimitation of an 
antigenic site precisely identifies a predicted penta peptide motif 
as the minimal antigenic determinant presented by a class I MHC 
molecule and recognized by a cytolytic T lymphocyte clone. 
Synthetic peptides have been derived from the amino-acid 
sequence of pp89, an immediate-early (JE) phase regulatory 
protein ofmurine cytomegalovirus17-20, The 19-mer P(161-179) 
contained within its 595 residues18 is an antigenic sequenceZ1 , 
This sequence HzN-161GRLMYDMYPHFMPTNLGPSI79_ 
ofthe growth factor causes only a small decrease in steadv-state 
pHi, but enormous increases in the rate at which the cell re covers 
from both acid (Fig. la) and alkali loads (Fig. 2c). This effect 
of A VP on pHi does not seem to be an isolated event, as we 
have found eight other growth factors that also produce only a 
small pHi decrease in the presence of HC0:J (data not shown). 
Thus, an important physiological effect of the growth factor is 
to maintain a near-normal pHi while stimulating several acid-
base transporters. 
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Table 1 Delimitation of the antigenic motif for CTL clone IE1 
Peptide concentration 
[log M] 
Recognition detection detection 
Peptide ( competition) limit saturation 
lI-mer: MYPHFMPTNLO + -7 to -6 -4 to -3 
lO-mers: MYPHFMPTNL + -9 to -8 -7 to -6 
YPHFMPTNLO + -8 to -7 -6 to -5 
9-mers: MYPHFMPTN -(-) 
YPHFMPTNL + -12 to -10 -9 to -7 
PHFMPTNLO +(-) -4 to -3 -2 
8-mers: YPHFMPTN -(-) 
PHFMPTNL +(-) -4 to -3 
7-mers: YPHFMPT 
PHFMPTN + -8 to -7 -4 
HFMPTNL + -5 to -4 
6-mers: YPHFMP 
PHFMPTN + -2 to -3 
HFMPTN + -2 
FMPTNL 
5-mer: HFMPT + -3 
4-mers: HFMP 
FMPT 
Dose-response titrations of peptides give the peptide molarities in 
solution required for detectable target formation (detection limit) and 
for optimal target formation (detection saturation), The concentration 
ranges are compiled from at least 3 and up to 12 independent 
experiments. 
COOH (one-letter code) contains the predicted motifHFMPTl4, 
By screening aseries of related peptides that had been reduced 
in length from both terminals (not all shown), we found that 
the nonapeptide YPHFMPTNL represents the optimal antigenic 
peptide (Fig. 1 and Table 1) for the cytolytic T lymphocyte 
(CTL) JEl doneZ2,23, Even though binding of peptides to dass 
I molecules has not yet been demonstrated directiy, the selective 
recognition on L/ L d cells implies that the L d molecule is the 
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Fig. 1 Cytolytic assays 
demonstrating L d_ 
restricted recognition of 
peptides by CTL clone 
IEI (a), and dose-
response titrations of pep-
tides (b). Each value in the 
peptide titrations rep-
resents the lysis deter-
mined from the plateau of 
a complete efIector-to-
target titration graph at a 
ratio of 20, and each value 
of % specific lysis is the 
me an of four replicate 
determinations. 
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efIector cells: The murine 
(BALB/c strain; MHCd ) 
CTL li ne IE1.13-IL was 
derived from clone lEI by 
recloning22.23 . Clone lEI 
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phenotype CD4-CDS-CD8+Thy-I+. L fibroblast transfectants: L/Ld cells were derived from L cells by transfection with the Ld gene, and 
L/Dd and L/Kd transfectants were provided by M. Cochet and J. P. Abastado (Institut Pasteur). Surface expression of the Ld , Dd and Kd 
moleeules was confirmed by cytofluorography with monoclonal antibodies. Synthetic peptides: Peptides were synthesized by using the 
Barany-Merrifield solid-phase technique on an Applied Biosystems Peptide Synthesizer, purified preparatively and analysed as described 
previously13. Preparation of target cells and cytolytic assay: Target cells were labelIed at 37°C for 1 h with Na2[51Cr]ü4' The radioactive cells 
were then distributed in aliquots of 105 cells and incubated in 0.2 ml for a further I h at 27 °C with peptides at defined molarities (J M 
corresponds to 1015 peptide molecules per cell) dissolved in RPMl 1640 culture medium supplemented with 2% of FCS. The highest peptide 
concentration tested was 10-2 M. This limit was imposed by the solubility of the peptides. After washing to remove excess peptide and "Cr, 
a standard 3-h cytolytic assay was performed at 37°C with 1,000 target cells and graded numbers of clone lEI CTL. Competition assays: The 
ability of peptides to compete with the optimal antigenic nonapeptide YPHFMPTNL was tested in two ways. Either the concentration of the 
antigenic peptide was kept constant at 10-7 M and the competitor peptide titrated up to 10-4 M, or the concentration of the competitor peptide 
was kept constant at 10-4 M and the antigenie peptide was titrated from 10-5 to 10-10 M. In both cases the L/Ld target cells were pre-incubated 
for 30 min with the competitor peptide before the antigenic peptide was added. 
receptor involved in the interaction with the T-cell antigen 
receptor (TCR) of clone JEl for the family of peptides tested 
(Fig. la). Titration ofthe nonapeptide YPHFMPTNL, the hep-
tapeptide PHFMPTN, and the pentapeptide HFMPT resulted 
in dose-response saturation curves showing thousandfold 
differences in antigenic potency (Fig. 1 b). The data refer to a 
one-hour incubation of target cells with peptide. Differences in 
antigenic potency are also refiected by the time needed for 
optimal target formation; five minutes is long enough to prepare 
an optimal nonapeptide target, which is in line with data for a 
high-affinity peptide24, whereas plateau lysis could be achieved 
with the pentapeptide only when the peptide pulse was prolon-
ged to two hours or more (not shown). Because clone lEI does 
not discriminate between nonapeptide and pentapeptide target 
once the target is formed, the limiting step is apparently the 
association between the peptide ligand and its MHC receptor 
on the target-cell surface. We therefore conclude that HFMPT 
forms the antigenic co re of the peptides by comprising both the 
complete epitope for the TCR of clone JEl and an agretope 
that is adequate, but not optimal for specification ofthe interac-
tion with Ld • 
The deletion of Tyrl (Y) from peptide YPHFMPTNL dimin-
ished and the deletion of Leu 9 (L) destroyed the antigenicity, 
and the resulting octapeptides PHFMPTNL and YPHFMPTN 
both also failed to compete with YPHFMPTNL (Table 1). 
According to the currently used theorem for classifying residues 
as T-cell contact residues or as MHC-molecule contact 
residues 12, Tyr 1 and Leu 9 would have been interpreted as 
residues contacting the MHC molecule. This conclusion, 
however, was proven incorrect by the findings that PHFMPTN, 
which lacks both residues, was> 103 -fold more antigenic than 
PHFMPTNL (Table 1) and could not be competed by a 103 -fold 
excess ofYPHFMPTN (not shown), although both octapeptides 
include the heptapeptide sequence entirely. Results compiled 
in Table 1 follow a consistent pattern from the pentameric core 
motif up to the nonapeptide size, in that symmetric additions 
of residues improved the antigenicity, whereas addition of 
residues at either end had a negative effect. 
This communication adds new aspects to the current under-
standing of the MHC molecule-peptide-TCR interaction. The 
first aspect concerns the minimal length of antigenic peptides. 
Until now, the shortest peptides reported as antigenic were 
heptapeptides presented by MHC class II molecules25.26. A 
recent study described a nonapeptide presented by an MHC 
class I molecule as minimal antigenic peptide ofthe glycoprotein 
of LCMy27. It should be emphasized that in our example 
systematic shortening from both termini was critical for the 
identification of the pentapeptide as the minimal antigenic pep-
tide. Since the sequence of this pentapeptide is a predicted 
pentameric motif, and as most motifs are tetrameric l4, recogni-
tion even of tetrapeptides may be possible. 
The second aspect concerns the classification of epitope and 
agretope residues. For the hen egg-white lysozyme peptide (52-
61), Allen et al. 12 defined residues as MHC-antigen contact 
residues when a substitution led to the loss of both antigenicity 
and the ability to compete with the unmodified antigenic peptide. 
With this approach and proposing a helical conformation, 
agretope residues were segregated from epitope residues. From 
a set of overlapping peptides, Sette et al. 28 predicted a heptameric 
co re in a planar conformation for the ovalbumin peptide (323-
339). In contrast to these examples, we have positively identified 
the motif HFMPT as an antigenic co re in pp89 peptides by 
demonstrating a direct antigenicity ofthe pentapeptide HFMPT. 
The important implication is that residues whose deletion causes 
loss of both antigenic potency and competitive ability are not 
necessarily agretope residues in the classical sense of MHC-
receptor binding sites. We propose that residues fianking an 
antigenic core motif can affect the antigenic potency positively 
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or negatively by their influence on peptide conformation. 
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Class I cross-restricted T cells reveal low 
responder allele due to processing 
of viral antigen 
Helen C. Bodmer, Frances M. Gotch 
& Andrew J. McMichael 
Institute for Molecular Medicine, lohn Radcliffe Hospital, 
Oxford OX39DU, UK 
Cytotoxic T Iymphocytes (CfL) recognize protein antigens which 
have been processed by the target cell and then presented in 
association with the relevant class I molecule of the major histo-
compatibility complex (MHC)I. Short synthetic peptides, which 
are able to associate directly with target cellsI, may substitute for 
these processed fragments in stimulating antigen-specific CfL 
responses. Using this approach, a dominant HLA-Al-restricted 
epitope has previously been mapped to residues 58-68 of influenza 
A virus matrix protein2• Here we report HLA-A2-restricted CTL 
which are also able to recognize this short synthetic peptide in 
association with HLA-Aw69, but which fail to recognize HLA-
Aw69 expressing cells infected with influenza A virus. Furthermore, 
individuals possessing HLA-Aw69 who respond to influenza A 
virus, do not respond to M58-68. These results imply that the low 
response to this epitope on infection of HLA-Aw69 individuals 
with influenza A is due to failure of the naturally processed product 
of matrix protein to associate with Aw69. 
Individuals who express the common HLA-A2 variant, HLA-
A2.I (HLA-A*0202 as defined in ref. 3), and who can mount a 
cytotoxic response to influenza infected target cells, following 
in vitro stimulation with virus have been shown, in all cases 
tested to date, to possess CTL that specifically recognize syn-
thetic peptides representing residues 56-68 of the matrix pro-
tein4 • Individuals who have other variants of A2, or the closely 
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Fig. 1 CTL are cross-restricted, recognizing peptide on both 
autologous and Aw69-expressing target cells. Recognition by CTL 
clone IAI0 from the donor 1M (A2, 2; B15, 51; DR4, 4) ofpeptides 
M57-58, M58-68, and M59-68 of influenza matrix protein on 
autologous BCL target cells (1M), three HLA-mismatched BCL, 
IDF (A26, w69; BI8,38; DR11,l1), RSH (A68, 68; B42,42; 
DR3,3) and PC (AJ,24; B37, 62; DR6, 6). Kj T = 1.5, peptides 
present throughout assay 10 J.LM. 
Methods. CTL clone IAIO was derived from a parent line from 
the donor, 1M. Peripheral blood Iymphocytes were separated from 
wh oie blood, stimulated initially with AjX31 virus (grown and 
stored as previously described l8) and maintained in culture by 
repeated stimulations with peptide M57-68, as previously 
described4 . CTL were c10ned by selection of CD8 positive cells 
(iabelled with B941 antibody from Dr C. Mawas, and fluorescein-
labelIed anti-mouse immunoglobulin) using an Ortho Cyto-
fluorograf cell sorter, into 96-well plates containing 104 irradiated 
BCL (pretreated with 50 J.LM M57-68) and IL-2 10 U mi-I (Cetus 
Corp.) in RPMI containing 10% fetal calf serum. Monoclonality 
was indicated by the presence of a single ß-chain gene rearrange-
ment on Southern blotting (data not shown). Cytotoxic activity 
was assessed by incubating EBV-transformed Iymphoblastoid cells 
(BCL), labelIed with SICr, with CTL and diluted peptide (where 
appropriate) for 4 h in round-bottomed 96-well plates. Per cent 
target lysis was calculated from the formula (E - MI D - M) x 100 
where E = experimental SICr release, M = release in presence of 
culture medium (always < 18%) and D = release by 5% Triton 
X-IOO. For details of the peptides see legend to Fig. 3. 
related allele HLA-Aw69, which differs by six amino acids from 
A2*0202 (listed in Table 1)5, did not respond to this region of 
matrix protein4 • 
We made several CTL !in es and clones from a single HLA-A2 
expressing individual, JM, some of which were able to recognize 
matrix peptide 56-68 in association with HLA-Aw69 as well as 
A2, although they were otherwise HLA-restricted (Fig. 2). CTL 
clone IAlO was able to recognize the short synthetic peptides 
M57-68, M58-68 and M59-68 in association with both the 
autologous (JM) HLA-A2-expressing EBV-transformed B lym-
phoblastoid celliine (BCL), and a BCL expressing Aw69 which 
did not share any HLA alleles with JM (Fig. 1), but did not 
recognize two other HLA mismatched BCL in the presence of 
these peptides. 
Although these matrix-specific A2-restricted CTL were able 
to recognize Aw69-expressing target cells in the presence of 
synthetic peptide, a discrepancy between recognition of A2 and 
Aw69 BCL was seen following A/X3I virus infection of the 
target cells (Fig. 2). Both autologous and A2-matched BCL were 
recognized following pretreatment with the peptide, or infection 
with influenza virus (Fig. 2a, e). In contrast Aw69-expressing 
BCL were very poorly recognized following virus infection, 
although they were weil recognized after peptide treatment (Fig. 
2b, C, f). In addition, virus-specific polyclonal CTL from an 
Aw69-expressing donor were unable to recognize the synthetic 
peptide M58-68 (Fig. 2d). Even with repeated stimulation of 
these latter CTL with M58-68 in vitro, we were unable to obtain 
a response from either oftwo Aw69-expressing (HLA identical) 
